H1N1 2009 Vaccine Manufacturing Process: Inactivated and Live-Attenuated
The 2009 H1N1 pandemic vaccines were produced via two platforms:
Inactivated (Split-Virion/Subunit) Vaccine
- Virus Collection: WHO-recommended seed strain from reference labs.
- Propagation: Growth in embryonated chicken eggs or mammalian cell culture.
- Harvest: Virus-containing allantoic fluid or cell supernatant collected.
- Inactivation: Formaldehyde or β-propiolactone destroys infectivity while preserving antigens.
- Purification: Centrifugation, filtration, chromatography remove host proteins, lipids, nucleic acids.
- Formulation: Antigen standardized; stabilizers, preservatives, and sometimes adjuvants (e.g., AS03, MF59) added.
- Quality Control: Sterility, potency (SRID), safety, endotoxin testing.
- Fill/Finish: Sterile vials/syringes; cold-chain distribution.
Live-Attenuated Influenza Vaccine (LAIV)
- Seed Virus: Same WHO strain.
- Attenuation: Cold-adapted, temperature-sensitive master donor virus (e.g., A/Ann Arbor/6/60) reassorted with H1N1 surface genes.
- Propagation: In embryonated eggs at 25–27°C.
- Harvest & Processing: Allantoic fluid pooled, clarified.
- Formulation: Stabilizers (sucrose, phosphate), preservatives; no adjuvant.
- Quality Control: Genetic stability, infectivity, temperature sensitivity, sterility.
- Distribution: Cold chain (2–8°C); intranasal sprayer device.
Both types underwent accelerated but rigorous clinical trials before emergency use authorization.
Viral Infections - Related Articles
- Immune Thrombocytopenia Purpura (ITP): Causes, Symptoms & Treatment
- Antiretroviral Therapy (ART): A Comprehensive History & Overview
- Understanding Trojan Viruses: Risks, How They Work, and Protection
- Cytomegalovirus (CMV): Risks for Immunocompromised Individuals and Pregnancy
- Do Disinfectants Kill Viruses? Understanding Effectiveness
- Understanding Shingles: Symptoms, Causes & Treatment
- Orf Virus: Symptoms, Transmission, and Human Infection
